The IIA1 monoclonal antibody specifically recognizes CD49e, a type I transmembrane glycoprotein which is also known as Integrin α5 Chain or VLA-5 α chain (VLA-5α). Following translation, CD49e is cleaved into two disulfide-linked chains of 135 and 25 kDa that associate with β1 integrin (CD29) to form the VLA-5 (Integrin α5/β1) complex. The VLA-5 complex is a well-established fibronectin receptor that is expressed on many cell types, including fibroblasts, endothelial cells, epithelial cells, platelets, thymocytes, T cells, B cells, the myeloid cell line U937, K562 and some melanoma cell lines. This clone inhibits α5β1 binding of ligands. It is useful for studies of the expression and function of this integrin.
The antibody was conjugated to an oligonucleotide that contains an antibody clone-specific barcode (ABC) flanked by a poly-A tail on the 3' end and a PCR handle (PCR primer binding site) on the 5' end. The ABC for this antibody was designed to be used with other BD AbSeq oligonucleotides conjugated to other antibodies. All AbSeq ABC sequences were selected in silico to be unique from human and mouse genomes, have low predicted secondary structure, and have high Hamming distance within the BD AbSeq portfolio, to allow for sequencing error correction and unique mapping. The poly-A tail of the oligonucleotide allows the ABC to be captured by the BD Rhapsody™ system or other oligo-dT-based capture systems. The 5' PCR handle allows for efficient sequencing library generation for Illumina sequencing platforms.